🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

How I treat secondary acute myeloid leukemia ashpublications.org/blood/article-… #leusm #AML

So pleased to see this paper from Charlotte Brierley and Giulia out in Nature Genetics! Please take a look at the summary thread from Charlotte. This was a really fun collaboration with John Crispino. Thanks to all the team, our funders and patients who donated samples.

🍕 🍷 learning, networking, & collaboration … must be time for #EHA2025 in #milan (well after clinic tomorrow) 🍕 🍷 ☀️ 🇮🇹

Feeling fatigued? Disconnected? Emotionally exhausted? You’re not alone. In the #YoungEHA session, Dr. Adela Perolla shares striking results from the pan-European survey: burnout is widespread among hematologists. It’s time to talk about it. #EHA2025

50% of European hematologists face high burnout. Women more so. Why? Fewer promotions, lower profession recognition, greater pressure balancing work & life, and persistent gender bias from superiors. Burnout isn't just personal. It's systemic. #EHA2025 #YoungEHA

#EHA2025 #youngEHA #ALL Novel targeted therapeutics for B-cell and T-cell ALL, presented by Dr. Nicola Gokbuget

#EHA2025 #ALL #leusm long-term follow up of CALGB 10403 trial presented by Dr. Wendy Stock, 10 yrs OS 56%. T-cell ALL no relapses after 3 yrs. 3 pts had t-MN. Late events in B-cell ALL after 3 yrs 25%.

Great to see the Keeshan Lab old and current members Edgar Andrews. Beautiful work with your posters - congratulations! UofG Cancer Sciences

CONGRESS | #EHA25 | PRESENTATION Vikas Gupta Vikas Gupta Princess Margaret Cancer Centre discusses management of accelerated and blast phase #MPN (MPN-AP/BP). Genetic profile of blast phase MPN different to de novo AML, little clinical trial data available as patients not usually eligible.

CONGRESS | #EHA2025 | PRESENTATION John Mascarenhas, Icahn School of Medicine at Mount Sinai shares preliminary results from the dose-escalation cohorts of the phase I INCA33989-101 and -102 trials evaluating INCA33989, a novel mutant calreticulin-specific monoclonal antibody therapy, in patients with

Exciting times for mutCALR MPNs - lovely data from the ET cohort presented in late breaking abstract at European Hematology Association. Rapid platelet control after just 2 doses with 89% of patients benefitting from a molecular response with INCA033989. MPN Voice MPN_Hub MPN Research Foundation

The Government is aiming for a significant expansion of clinical trials in the UK, with plans to use the NHS app to encourage millions of people in England to take part in the search for new treatments: theguardian.com/society/2025/j… (1/5)

The Institute of Cancer Research is hiring a new Group Leader! A unique opportunity to establish your own research group at one of the UK’s leading cancer institutes. Competitive package, strong senior support, and access to world-class facilities. nature.com/naturecareers/…

The devil might be in the detail, but the VERONA trial (aza-ven vs aza in high risk MDS) didn’t meet the primary endpoint. news.abbvie.com/2025-06-16-Abb…

With the disappointing announcement today by AbbVie of the negative result of the VERONA venetoclax/azacitidine trial, that brings the tally to (by my count) 17 consecutive negative randomized drug trials in higher-risk #MDSsm. This is a slide I made summarizing them./1

David Walsh and Gerry McCartney, co-authors of 'Social Murder? Austerity and Life Expectancy in the UK', discuss the ongoing impact and human cost of government austerity policies. Bristol Uni Press UofG Public Health UofG Social Sciences youtube.com/watch?v=5wFRQC…

Please join us in York!

Another podcast released 🤩 - the amazing Adrian Shields talks us through common immunological queries in haematology and how to manage them. From A&G advice to managing 2ndry immune def.. it’s all in there! Available on all the usual platforms and at blooducation.co.uk/portfolio/comm….

📣 Cell developmental state matters in B-ALL. Our study out today in ⁦Nature Cancer⁩: Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features | Nature Cancer nature.com/articles/s4301…

Detecting and quantifying clonal selection in somatic stem cells | Nature Genetics. So pleased to share this work. It is one of the most important pieces of work we have done. Huge thanks to all. More improvements on SCIFER to come! nature.com/articles/s4158…